Pharmaceuticals company Caplin Point Laboratories announced Q2FY26 results Revenue from Operation: Rs 534.0 crore compared to Rs 483.1 crore during Q2FY25, change 10.5%. EBITDA: Rs 219.5 crore compared to Rs 185.5 crore during Q2FY25, change 18.3%. EBITDA Margin: 38.9% for Q2FY26. PBT: Rs 201.0 crore compared to Rs 168.5 crore during Q2FY25, change 19.3%. PAT: Rs 160.2 crore compared to Rs 130.8 crore during Q2FY25, change 22.5%. C.C. Paarthipan, Chairman, said: "Consistency has been the cornerstone of Caplin’s journey. We are pleased to report another strong set of results, fully aligned with our long-term growth path and guidance. Our unwavering focus on cashflows, profitability, and revenue growth continues across all segments of the business, complemented by an equally strong commitment to compliance and governance. We are leveraging our deep understanding of smaller Latin American markets through our subsidiaries in the front end, together with our R&D; and supply chain excellence at the back end, to create a powerful foundation for expansion into larger markets such as Mexico, Chile, Colombia, and eventually Brazil. Our relentless emphasis on compliance and operational productivity continues to drive robust growth in regulated markets like the U.S. and Canada, and we expect this segment to represent an even greater share of our business in the coming years. Meanwhile, our China 2.0 strategy positions us to fast-track entry into high-potential areas such as Biosimilars and Peptides — segments traditionally dominated by larger players. The building blocks we are putting in place from now and over the next couple of year will set Caplin on a strong, multi-year growth trajectory, underpinned by the same consistency, discipline, and performance metrics that have defined us thus far." Result PDF
Pharmaceuticals company Caplin Point Laboratories announced Q1FY26 results Gross Margin for Q1FY26 is 61.7% vs 59.6% in Q1FY25 aided by new product launches across existing and new markets. EBITDA Margin for Q1FY26 is at 37.7% vs 35.7% in Q1FY25. Basic EPS increased by 23.1% to Rs 20.10 in Q1FY26 compared to Rs 16.32 in Q1FY25. Cash Flow from Operations in Q1FY26 is Rs 118 crore vs Rs 96 crore in Q1FY25. Free Cash Flow is Rs 53 crore (after Capex investment of Rs 65 crore) in Q1FY26 as compared to Rs 59 crore (after capex investment of Rs 37 crore) in Q1FY25. Geographical revenue composition between Emerging Markets (Latin America & Africa) and US for Q1FY26 is in the range of 79% and 21% respectively. CSL’s Revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for Q1FY26 in the range of 85% and 15% respectively. As of 30th June 2025, Inventories are at Rs 324 crore - 56% Stock at the warehouses, close to the customer; In Transit 13%; 31% in India. Receivables are at 114 days. As of 30th June 2025, Free Cash reserves are at Rs 1,237 crore and Total Liquid Assets at Rs 2,207 crore. C.C. Paarthipan, Chairman, said: "We’re putting in place the right building blocks for both Emerging Markets and Regulated markets. We're making good progress with finalizing partners and also filing dossiers in our new key target markets of Mexico, Chile, USA etc. We're also aiming to gradually onshore some strategic manufacturing at important locations in Latin America and US, and taking the first steps of acquiring land/buildings for the same. We've also launched our second innings from China which will focus more deeply on high-tech products like Biosimilars, Peptides etc. We're strengthening our Marketing and Regulatory teams at both India and LatAm with seasoned professionals, to ensure our growth momentum remains steady. We continue to have a sharp focus on consolidating our presence in the existing markets with expansion on products, profits and cashflows." Result PDF
Pharmaceuticals company Caplin Point Laboratories announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Gross Margin: 60% vs. 56.6% in Q4FY24 — aided by new product launches across existing and new markets. Revenue from Operations: Rs 502.5 crore vs. Rs 453.2 crore in Q4FY24 — up 10.9% YoY. EBITDA: Rs 193.8 crore vs. Rs 162.5 crore in Q4FY24 — up 19.2% YoY. EBITDA Margin: 36.7% vs. 34.5% in Q4FY24 Profit After Tax (PAT): Rs 145.3 crore vs. Rs 121.2 crore in Q4FY24 — up 19.8% YoY. FY25 Financial Highlights: FY25 Total Revenue at Rs 2034 crore; an increase of 15.5% YoY FY 25 PAT at Rs 541 crore; (Growth of 17.3% over FY24) EBITDA Margin: 36.5% vs. 35.1% in FY24 Basic EPS increased by 17.2% to Rs 70.57 in FY25 compared to Rs 60.19 in FY24. Cash Flow from Operations in FY25 is Rs 432.39 crore vs Rs 318 crore in FY24. CSL's Total revenue crosses Rs 366 crore, an increase of 15% over FY24. US Market FY25 EBIDTA crosses Rs 102 crore (Growth of 71% over FY24) Free Cash Reserves at Rs 1,180 crore; Liquid Assets at Rs 2,148 crore Commenting on the performance, C.C. Paarthipan, Chairman said: "We’re delighted to close out another year with excellent Top and Bottom Line Growth, and continue our progress on being a benchmark when it comes to Cashflows. Our front end in the US is taking shape at a good pace and we expect this entity to drive strong growth for the parent company over the next few years. We’re once again focusing on getting back to Asset Light outsourcing using our Second Innings at China, with import of Peptides and Key starting materials for Biosimilars, which we plan to file and launch in our Emerging Markets where we have a significant presence already. With our API entities coming on stream in the very near future, we can truly envision Caplin being a fully integrated global Pharma player in the years to come." Result PDF
Conference Call with Caplin Point Laboratories Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Caplin Point Laboratories announced Q3FY25 results Revenue: Rs 493.0 crore compared to Rs 435.5 crore during Q3FY24, change 13.2%. EBITDA: Rs 193.7 crore compared to Rs 159.5 crore during Q3FY24, change 21.4%. PBT: Rs 177.3 crore compared to Rs 145.4 crore during Q3FY24, change 21.9%. PAT: Rs 140.1 crore compared to Rs 119.8 crore during Q3FY24, change 16.9%. Gross Margin for Q3FY25 is 60.4% vs 56.3% in Q3 FY24. EBITDA Margin for Q3FY25 is at 36.9% vs 35.2% in Q3 FY24. As of 31st December 2024, Inventories are at Rs 333 crore - 52% Stock at the warehouses, close to the customer; In Transit 18%; 30% in India. Receivables is at 118 days. As of 31st December, 2024 Free Cash reserves are at Rs 1,081 crore and Total Liquid Assets at Rs 2,042 crore. C.C. Paarthipan, Chairman, said: We’re happy to report another strong set of numbers for this quarter, underlining our sharp focus on consistency in all areas. The company has shown encouraging progress within a very short period when it comes to the launch of our own label in the US, and with consistent on-time approvals, we’re confident that this entity will deliver robust growth to the organization. We’re making good progress in our key emerging markets of Mexico and Chile, and we can start to see tangible growth from these areas in the next couple of years. The company is well positioned for continued growth in all parameters, with benchmark cashflows for multiple years to come. Result PDF